AstraZeneca/Actavis Antibiotic Faces Limited Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA allowed flexibility in AstraZeneca/Actavis’ gram-negative antibiotic development program, but agency’s advisory committee briefing documents propose more restrictive label than companies are seeking.